Poliovirus vaccine live oral
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Poliovirus vaccine live oral
- poliovirus vaccine live oral
- Poliovirus vaccine live oral
- ChEMBL ID
- CHEMBL2108778
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir-
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Malaria
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Poliomyelitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007450
- Subject identifier
- D011051
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007450
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT03554798
- NCT04232943
- NCT04529538
- NCT04540185
- NCT05155579
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (30)
- A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
- A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
- A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
- A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
- Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
- Diarrhea and Bivalent Oral Polio Vaccine Immunity
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine
- Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)
- Immunogenicity of Inactivated and Live Polio Vaccines
- Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
- Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
- Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth
- IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
In development for (4)
- COVID-19 Phase 3
- Malaria Phase 1
- Poliomyelitis Phase 2
- Severe acute respiratory syndrome Phase 3